MDMA — Pharmala Biotech Holdings Balance Sheet
0.000.00%
- CA$10.86m
- CA$10.00m
- CA$0.61m
- 67
- 10
- 13
- 19
Annual balance sheet for Pharmala Biotech Holdings, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | 2025 August 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2.47 | 0.852 | 0.195 | 0.419 | 0.961 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.06 | 0.051 | 0.223 | 0.211 | 0.063 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 2.53 | 1.09 | 0.714 | 1.04 | 1.65 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.002 | 0.004 | 0.002 | 0 | 0.003 |
| Net Intangible Assets | |||||
| Total Assets | 2.79 | 2.33 | 2.41 | 2.9 | 3.42 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.138 | 0.424 | 1.03 | 0.917 | 0.962 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.138 | 0.424 | 1.03 | 0.917 | 0.962 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 2.66 | 1.91 | 1.38 | 1.98 | 2.46 |
| Total Liabilities & Shareholders' Equity | 2.79 | 2.33 | 2.41 | 2.9 | 3.42 |
| Total Common Shares Outstanding |